AI Article Synopsis
- Total serum IgE levels were measured in 219 patients with allergic disorders (asthma, rhinitis, urticaria) compared to 240 healthy individuals, revealing significantly higher IgE levels in allergic patients.
- Healthy males exhibited higher mean IgE levels (181 IU/ml) than females (99 IU/ml), with levels peaking in those aged 15 to 24 and decreasing after 55.
- Positive skin tests for allergens were found in a majority of patients with asthma (60%), rhinitis (51%), and urticaria (46%), but the difference in IgE levels between those with positive and negative tests was not statistically significant.
Article Abstract
Total serum IgE levels were estimated in 219 patients with various allergic disorders (119 with bronchial asthma, 68 with allergic rhinitis and 32 with urticaria) and 240 healthy age matched subjects. Serum IgE levels were significantly (P < 0.001) higher in healthy males (mean 181 IU/ml) than females (mean 99 IU/ml). Higher levels were found in the age group 15 to 24 years and lowest in over 55 years. Males had higher IgE levels than females at any given age. Mean IgE levels were significantly (p < 0.001) higher in all three groups of patients than in healthy subjects. Among all age groups, the difference in mean IgE levels between allergic subjects and controls was significant. Positive skin test reactivity (to pollen and dust allergens) was found in 60% patients with asthma, 51% with allergic rhinitis, 46% with urticaria and in 4.5% healthy subjects. Patients with positive skin test had higher mean IgE levels as compared to those with negative skin test, but the difference was insignificant.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Construction and validation of a predictive model for allergic rhinitis complicating children with bronchial asthma.
Allergol Immunopathol (Madr)
January 2025
Department of Pediatric Respiratory Medicine, Anhui Provincial Children's Hospital, Hefei City, Anhui Province, China.
This study aimed to investigate the factors influencing the complication of allergic rhinitis in children with bronchial asthma and to construct a nomogram model to predict the occurrence of allergic rhinitis. A total of 190 children with bronchial asthma admitted to our hospital from August 2020 to August 2024 were retrospectively analyzed. The children were randomly divided into the training cohort (133 cases) and validation cohort (57 cases) in a ratio of 7:3.
View Article and Find Full Text PDFTrends in prescribing montelukast in patients with asthma in real-life: Results from the Turkish adult asthma registry.
Allergol Immunopathol (Madr)
January 2025
Department of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey.
Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.
View Article and Find Full Text PDFChanges in serum periostin levels in uncontrolled asthma in children (DADO phase 2 study).
Allergol Immunopathol (Madr)
January 2025
Department of Biological Sciences, University of Extremadura, Spain.
Objective: Asthma is an inflammatory airway condition and the most common chronic disease in children. However, there is a lack of biological markers for asthma, especially in children. This study aimed to analyze the changes in periostin levels in children with uncontrolled asthma after 12 months of optimized management.
View Article and Find Full Text PDFCT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study.
Allergy
January 2025
St John's Institute of Dermatology, Guy's Hospital, London, UK.
Background: This study compared the therapeutic equivalence of CT-P39 (an omalizumab biosimilar) and EU-approved reference omalizumab (ref-OMA) in patients with chronic spontaneous urticaria.
Methods: This double-blind, randomized, active-controlled Phase 3 study (NCT04426890) included two 12-week treatment periods (TPs). In TP1, patients received CT-P39 300 mg, ref-OMA 300 mg, CT-P39 150 mg, or ref-OMA 150 mg.
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II).
Immunotherapy
January 2025
Blauvelt Consulting, LLC, Lake Oswego, OR, USA.
Aim: Lebrikizumab is an interleukin (IL)-13 inhibitor that specifically blocks IL-13 signaling. Here, we report the effects of lebrikizumab on asthma serum biomarkers in 2 phase 3 clinical studies.
Methods: LAVOLTA I and LAVOLTA II are replicate, double-blind, placebo-controlled trials with 52-week placebo-controlled treatment periods that evaluated lebrikizumab 37.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!